BACKGROUND: Multiple sclerosis (MS) is a progressive autoimmune disease of the central nervous system that is often disabling and for which there is currently no cure, though disease-modifying treatment is now available. The aim of this study is to describe the current values of the direct costs of multiple sclerosis (MS) in the Czech Republic. METHODS: Attention is focused on direct medical costs. The costs were monitored in the Czech Republic among 5673 patients in the period between 2011 and 2015. These costs included complex, special and targeted visits at the neurologist, blood collection and the costs of hospitalisation. The results refer to the diagnoses according to the International Statistical Classification of Diseases and Related Health Problems. The attention is focused on MS G35 (NS; brain stem; spinal cord; disseminated; generalised). RESULTS: The average total direct costs per patient per year are 4838.1 €. Not every patient has to be hospitalised during the year, and not every patient has prescribed medication. According to the above data, 12% of patients are hospitalised and 55% of patients are prescribed medication. The minimum average cost per patient without medication and hospitalisation is 54.1 €. CONCLUSION: Cost evaluation across countries is difficult due to the different evidence. If only selected direct costs considered in this study are compared, the absolute economics burden increases over time. The only statistically significant difference in the average price and the time spent is between 2012 and 2013, where the correlation value is 0.597.

Biomedical Research Centrum University Hospital Hradec Králové Sokolská 581 Hradec Kralove Czech Republic

Centre of Basic and Applied Research Faculty of Informatics and Management University of Hradec Kralove Hradec Kralove Czech Republic

Department of Economics Faculty of Informatics and Management University of Hradec Králové Hradec Kralove Czech Republic

Department of Neurology Faculty of Medicine in Hradec Králové Charles University Prague Hradec Kralove Czech Republic

See more in PubMed

J Med Econ. 2013;16(5):639-47 PubMed

Ann Neurol. 2009 Oct;66(4):513-20 PubMed

Int J Prev Med. 2014 Sep;5(9):1131-8 PubMed

Neuropsychiatr Dis Treat. 2015 Sep 11;11:2349-54 PubMed

Mult Scler. 2012 May;18(5):662-8 PubMed

Neurology. 1996 Apr;46(4):907-11 PubMed

Mult Scler. 2017 Aug;23(2_suppl):41-52 PubMed

Eur Neuropsychopharmacol. 2011 Feb;21(2):180-91 PubMed

Neurol Sci. 2015 Feb;36(2):227-34 PubMed

Lancet Neurol. 2004 Feb;3(2):104-10 PubMed

Eur J Health Econ. 2017 Nov;18(8):979-986 PubMed

Neurology. 2008 Jul 8;71(2):129-35 PubMed

Autoimmun Rev. 2010 Mar;9(5):A387-94 PubMed

Neurology. 2015 May 26;84(21):2185-92 PubMed

Curr Alzheimer Res. 2015;12(9):903-11 PubMed

Expert Rev Pharmacoecon Outcomes Res. 2014 Jun;14(3):451-8 PubMed

Mult Scler. 2017 Jul;23(8):1123-1136 PubMed

Clin Neurol Neurosurg. 2002 Jul;104(3):182-91 PubMed

Neurol Sci. 2016 Dec;37(12):1917-1922 PubMed

Ann Neurol. 2007 Apr;61(4):288-99 PubMed

J Alzheimers Dis. 2016 Oct 4;54(3):1123-1133 PubMed